Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results

DOI PDF Web Site Web Site 1 Citations

Journal

  • Leukemia

    Leukemia 31 (11), 2529-2531, 2017-08-03

    Springer Science and Business Media LLC

Citations (1)*help

See more

Keywords

Report a problem

Back to top